GLP-1 myth busters: 10 things social media gets wrong

Dr Saran Seker (MBBS, Aus)

Sep 8

2 min read

Updated: Oct 1

Myth 1: 'Using medication is cheating'

Obesity is a chronic, multifactorial disease. Medication can be one evidence-based component of care, just as pharmacotherapy is used in other chronic conditions. Lifestyle remains important.

Myth 2: 'GLP-1s melt fat'

These medicines affect appetite, satiety and metabolic pathways. Weight loss follows changes in energy balance; the drug is not directly dissolving fat.

Myth 3: 'If you are not nauseous, it is not working'

Nausea is an adverse effect, not a marker of efficacy. More side effects do not mean more successful treatment.

Myth 4: 'Everyone loses 20%'

Trial percentages are averages and depend on the medicine, population and duration. Individual responses vary.

Myth 5: 'You should reach the highest dose as quickly as possible'

Dose escalation is designed around the product regimen and tolerability. The highest possible dose is not a prize.

Myth 6: 'GLP-1s are only diabetes drugs'

The class has a major history in diabetes treatment, but specific products are also approved for chronic weight management in appropriate populations.

Myth 7: 'All GLP-1s are the same'

Liraglutide, semaglutide and dual GIP/GLP-1 treatment such as tirzepatide have different pharmacology, dosing and evidence.

Myth 8: 'Stopping means you will definitely regain everything'

Weight regain is common in withdrawal studies, but the amount and trajectory vary. Absolute statements about every patient are inaccurate.

Myth 9: 'Generic means fake'

An appropriately approved generic and a falsified or unverified product are not the same thing. Regulatory status, manufacturing and traceability matter.

Myth 10: 'If it is on social media, someone must have checked it'

Popularity is not evidence. Before trusting a claim, look for the trial, the study population, duration, comparator and actual outcome measured.

The simple evidence check

A useful habit is to ask: Was it studied in humans? Was there a comparison group? How many people? How long? What was the absolute result? Were side effects reported? And does the claim apply to people like me?

That is a better filter than likes, followers or before-and-after photos. References:

Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021. DOI: 10.1056/NEJMoa2032183. PubMed
Endocrine Society of India. Clinical Practice Guidelines for the Evaluation and Management of Obesity in India: 2025 Update. PubMed Central (PMC)
American Diabetes Association. Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity. 2026.

Written and clinically reviewed by: Dr Saran Seker, MBBS (Aus), Chief Medical Officer

Last reviewed: September 2026